Skip to main content
OpenTrials
Completed

NCT Number: NCT05322668

Tolerance of Cyto-selective Difluoroethane-based Cryotherapy

Cryotherapy is more and more used to improve skin appearance. Devices using difluoroethane, manufactured by CRYONOVE PHARMA, are already available on the local and international markets, e.g. CRYOBEAUTY MAINS and CRYOBEAUTY CORPS.

However, the cryogenic gas (conventional cryotherapy - liquid nitrogen) creates a dermabrasion of the skin surface and person receiving this kind of treatment presents an impaired skin during a few days following the treatment as temporary damage of stratum corneum, erythema, scars, burns.

Following the side effects occurring after conventional cryotherapy application, it seems interesting for the sponsor to select other sequences of a cryogenic spray (4 prototypes of devices) which could be used for lentigo treatment with a same benefit for the consumers without any safety outcomes.

This study will assess the use of different prototypes with a sequence of application of cryogenic gas which reaches a higher temperature than those which used with the reference device, in order to increase the acceptability of the device.

(CS4_3) proof of concept, interventional, monocentric, aims to evaluate the tolerance of cryotherapy treatments applied on healthy skin on the back of the hands.

The main objective of the study is to evaluate on phototype V and VI, the tolerance of 4 different conditions of cryotherapy treatments (4 prototypes) applied on healthy skin on the back of the hands.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solar Lentigo

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

VIDNOVLENNYA medical center

Zhytomyr, 10014, Ukraine

About this study

Prototypes (812A-v1), (812C-v1), (812D-v1) and (812F-v1) will be applied on hands areas by the same order for all volunteers using a reposition mask. On each hand 2 devices will be attributed starting from the middle point of the hand toward to the lateral internal and lateral external edges of the hand. The distance between 2 treatment areas will be 2 cm.

Each area will be treated 1 time during the study at D0. The treatment will starts from right hand with prototypes (812A-v1) and (812C-v1), then left hands with the prototypes (812D-v1) and (812F-v1) .

Prior to any study device application, the dermatologist will assess the adverse events.

The dermatologist will verify that the skin has not been treated by cosmetic products (no presence of cream that could interfere with the treatment) and is dry.

The procedure will take place at the investigation site. An operator previously trained by the dermatologist will apply the study device to the patient's hand.

Subjects will lie down and the device will be administered upside down.

The prototypes will be applied 10 minutes apart so that pain can be measured without interference from application to application.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female or male.
  • Ages > 18.
  • Phototype V et VI (according with Fitzpatrick scale)
  • Agreeing not to be exposed to the sun (or artificial UV) during the study.
  • Informed, having undergone a general clinical examination attesting to his/her ability to participate in the study.
  • Having given written consent for participation in the study.
  • No suspicion of carcinoma after investigation by a dermatologist.

Exclusion criteria

  • Having performed cosmetic treatments (exfoliants, scrubs or self-tanners, facials, UV ...) in the month before the start of the study, at the level of the hand.
  • Having applied a depraving product in the month prior to the start of the study, at the hands (except cleansing products).
  • Having performed cosmetic treatments in a dermatologist (laser, IPL (Intensed pulsed light), peeling, creams, cryotherapy ...), on the hands in the last 6 months.
  • With dermatosis, autoimmune disease, systemic, chronic or acute disease, or any other pathology that may interfere with treatment or influence the results of the study (people with diabetes or circulatory problems,allergic to cold, Raynaud's syndrome...).
  • Receiving treatment by general or local (dermo corticoids, corticosteroids, diuretics ...) likely to interfere with the evaluation of the parameter studied.
  • Participating in another study or being excluded from a previous study.
  • Unable to follow the requirements of the protocol.
  • Vulnerable: whose ability or freedom to give or refuse consent is limited.
  • Major protected by law (tutorship, curatorship, safeguarding justice...).
  • People unable to understand, read and write English/French/Ukrainian language. However, the impartial witness will be introduced to current study to make translations if necessary, during all course of the study for each volunteer and respective section for signature and date will be implemented to the "Information Sheet and Informed Consent Form".
  • Unable to be contacted urgently over the phone.

For female subjects:

  • Pregnant woman (or wishing to be pregnant during study) or while breastfeeding.
  • A woman, who does not use effective methods of contraception.

Treatment and study plan

Prototypes (812A-v1), (812C-v1), (812D-v1) and (812F-v1)

Device

All the subjects will receive all the treatment in the same order.

On each hand 2 devices will be attributed as follow:

  • Prototypes (812A-v1) will be applied on an area of the back of the patient's right hand, on healthy skin
  • Prototypes (812C-v1) will be applied on an area of the back of the patient's right hand, on healthy skin
  • Prototypes (812D-v1) will be applied on an area of the back of the patient's left hand, on healthy skin
  • Prototypes (812F-v1) will be applied on an area of the back of the patient's left hand, on healthy skin

Primary outcomes

  1. Change from baseline skin hyperpigmentation

    Time frame: Day 0, Day 2, Day 7, Day 21, Day 56

    This outcome is a tolerance assessment criteria. Clinical evaluation of hyperpigmentation on each selected and treated area will be performed by a Dermatologist using the Investigator's Global Assessment likert 6 points scale ranged from 0 to 5: 0=Clear of hyperpigmentation, 1= Almost clear of hyperpigmentation, 2=mild, but noticeable hyperpigmentation, 3=moderate hyperpigmentation (medium brown in quality), 4=severe hyperpigmentation (dark brown in quality), 5= very severe hyperpigmentation (very dark brown, almost black in quality)

  2. Change from baseline skin hypopigmentation

    Time frame: Day 0, Day 2, Day 7, Day 21, Day 56

    This outcome is a tolerance assessment criteria. Clinical evaluation of hypopigmentation on each selected and treated area will be performed by a Dermatologist using a likert 5 points scale ranged from 0 to 4: 0=no hypopigmented lesion, 1= very slight area of hypopigmentation of very small size and very slightly fairer than the surrounding skin, 2= slight area of hypopigmentation of small size and slightly fairer than the surrounding skin, 3= moderate : area of hypopigmentation of moderate size and much fairer than the surrounding skin, 4= severe : area of hypopigmentation of large size and much fairer than the surrounding skin.

  3. Change from baseline skin appearance (Edemas, blisters, bubbles, scars, erythema)

    Time frame: Day 0, Day 2, Day 7, Day 21, Day 56

    his outcome is a tolerance assessment criteria. Clinical visual evaluation of selected area and surrounded spotless skin area around the spot skin will be performed. A likert scale in 5 points (0 to 4) will be used : 0=none; 1=very mild; 2=mild; 3=moderate; 4=severe.

  4. Change from baseline skin sensation (itching, tingling, burning sensations)

    Time frame: Day 0, Day 2, Day 7, Day 21, Day 56

    This outcome is a tolerance assessment criteria. Clinical visual evaluation of selected lentigo spots and around the spot skin will be performed. A likert scale in 5 points (0 to 4) will be used : 0=none; 1=very mild; 2=mild; 3=moderate; 4=severe.

  5. Post treatment pain

    Time frame: Day 0

    This outcome is a tolerance assessment criteria. The pain of the treatment will be assessed by the VAS (Visual Analogue Scale). Pain intensity is measured in millimeters by the distance from the position of the mark to the "no pain" extremity.

  6. Other unexpected events

    Time frame: at Day0, Day2, Day7, Day21 and Day56

    This outcome concerns the occurence of the adverse events

Sponsors and collaborators

Lead sponsor

Cryonove Pharma

Industry

Collaborators

  • CEISO
  • Dermatech
  • INNOVSOLUTION

Registry information

Official study title

Evaluation of the Tolerance of Cyto-selective Difluoroethane-based Cryotherapy

Acronym: AGILE3

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Apr 12, 2022
Registry last updated
Aug 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.